[1] S. Vaughan, J.I. Coward, R.C. Bast, Jr., A. Berchuck, J.S. Berek, J.D. Brenton, G. Coukos, C.C. Crum, R. Drapkin, D. Etemadmoghadam, M. Friedlander, H. Gabra, S.B. Kaye, C.J. Lord, E. Lengyel, D.A. Levine, I.A. McNeish, U. Menon, G.B. Mills, K.P. Nephew, A.M. Oza, A.K. Sood, E.A. Stronach, H. Walczak, D.D. Bowtell, F.R. Balkwill, Rethinking ovarian cancer: recommendations for improving outcomes, Nat Rev Cancer 11(10) (2011) 719-25.
[2] E.A. Eisenhauer, Real-world evidence in the treatment of ovarian cancer, Ann Oncol 28(suppl_8) (2017) viii61-viii65.
[3] I. Tsibulak, A.G. Zeimet, C. Marth, Hopes and failures in front-line ovarian cancer therapy, Crit Rev Oncol Hematol 143 (2019) 14-19.
[4] M.F. Clarke, Clinical and Therapeutic Implications of Cancer Stem Cells. Reply, N Engl J Med 381(10) (2019) e19.
[5] F. Reim, Y. Dombrowski, C. Ritter, M. Buttmann, S. Hausler, M. Ossadnik, M. Krockenberger, D. Beier, C.P. Beier, J. Dietl, J.C. Becker, A. Honig, J. Wischhusen, Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells, Cancer Res 69(20) (2009) 8058-66.
[6] Y. Miao, H. Yang, J. Levorse, S. Yuan, L. Polak, M. Sribour, B. Singh, M.D. Rosenblum, E. Fuchs, Adaptive Immune Resistance Emerges from Tumor-Initiating Stem Cells, Cell 177(5) (2019) 1172-1186 e14.
[7] M. Lawrence, S. Daujat, R. Schneider, Lateral Thinking: How Histone Modifications Regulate Gene Expression, Trends Genet 32(1) (2016) 42-56.
[8] M.T. McCabe, H.P. Mohammad, O. Barbash, R.G. Kruger, Targeting Histone Methylation in Cancer, Cancer J 23(5) (2017) 292-301.
[9] Z. Meng, Y. Liu, J. Wang, H. Fan, H. Fang, S. Li, L. Yuan, C. Liu, Y. Peng, W. Zhao, L. Wang, J. Li, J. Feng, Histone demethylase KDM7A is required for stem cell maintenance and apoptosis inhibition in breast cancer, J Cell Physiol (2019).
[10] S.M. Stief, A.L. Hanneforth, S. Weser, R. Mattes, M. Carlet, W.H. Liu, M.D. Bartoschek, H. Dominguez Moreno, M. Oettle, J. Kempf, B. Vick, B. Ksienzyk, B. Tizazu, M. Rothenberg-Thurley, H. Quentmeier, W. Hiddemann, S. Vosberg, P.A. Greif, K.H. Metzeler, G. Schotta, S. Bultmann, I. Jeremias, H. Leonhardt, K. Spiekermann, Loss of KDM6A confers drug resistance in acute myeloid leukemia, Leukemia (2019).
[11] S. Ramadoss, S. Sen, I. Ramachandran, S. Roy, G. Chaudhuri, R. Farias-Eisner, Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance, Oncogene 36(11) (2017) 1537-1545.
[12] H. Sakaki, M. Okada, K. Kuramoto, H. Takeda, H. Watarai, S. Suzuki, S. Seino, M. Seino, T. Ohta, S. Nagase, H. Kurachi, C. Kitanaka, GSKJ4, A Selective Jumonji H3K27 Demethylase Inhibitor, Effectively Targets Ovarian Cancer Stem Cells, Anticancer Res 35(12) (2015) 6607-14.
[13] P.A. Cloos, J. Christensen, K. Agger, A. Maiolica, J. Rappsilber, T. Antal, K.H. Hansen, K. Helin, The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3, Nature 442(7100) (2006) 307-11.
[14] Y. An, H. Cai, Y. Zhang, S. Liu, Y. Duan, D. Sun, X. Chen, X. He, circZMYM2 Competed Endogenously with miR-335-5p to Regulate JMJD2C in Pancreatic Cancer, Cell Physiol Biochem 51(5) (2018) 2224-2236.
[15] N. Li, D. Jiang, Jumonji domain containing 2C promotes cell migration and invasion through modulating CUL4A expression in lung cancer, Biomed Pharmacother 89 (2017) 305-315.
[16] J. Garcia, F. Lizcano, KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer, Breast Cancer (Auckl) 10 (2016) 169-175.
[17] Z.Q. Yang, I. Imoto, Y. Fukuda, A. Pimkhaokham, Y. Shimada, M. Imamura, S. Sugano, Y. Nakamura, J. Inazawa, Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines, Cancer Res 60(17) (2000) 4735-9.
[18] S.C. Parte, S.K. Batra, S.S. Kakar, Characterization of stem cell and cancer stem cell populations in ovary and ovarian tumors, J Ovarian Res 11(1) (2018) 69.
[19] G. Liu, A. Bollig-Fischer, B. Kreike, M.J. van de Vijver, J. Abrams, S.P. Ethier, Z.Q. Yang, Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer, Oncogene 28(50) (2009) 4491-500.
[20] X. Yuan, J. Kong, Z. Ma, N. Li, R. Jia, Y. Liu, F. Zhou, Q. Zhan, G. Liu, S. Gao, KDM4C, a H3K9me3 Histone Demethylase, is Involved in the Maintenance of Human ESCC-Initiating Cells by Epigenetically Enhancing SOX2 Expression, Neoplasia 18(10) (2016) 594-609.
[21] J.P. Mallm, P. Windisch, A. Biran, Z. Gal, S. Schumacher, R. Glass, C. Herold-Mende, E. Meshorer, M. Barbus, K. Rippe, Glioblastoma initiating cells are sensitive to histone demethylase inhibition due to epigenetic deregulation, Int J Cancer (2019).
[22] K. Agger, K. Nishimura, S. Miyagi, J.E. Messling, K.D. Rasmussen, K. Helin, The KDM4/JMJD2 histone demethylases are required for hematopoietic stem cell maintenance, Blood (2019).
[23] X. Wang, A. Spandidos, H. Wang, B. Seed, PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update, Nucleic Acids Res 40(Database issue) (2012) D1144-9.